DPA714

Phase 2Small molecule

SSt. Jude Children's Research Hospital

DPA714 is one of 4 small molecule programs targeting Neuroinflammation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroinflammationActive, not recruiting

NeuroinflammationPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Neuroinflammation

#DrugCompanyPhaseTrials

Celebrex

PPhiladelphia Eye Associates

Approved

2 2

DPA-714-PET/MRI

UUniversity of Alabama at Birmingham

Phase 1

1 3

DPA714

SSt. Jude Children's Research Hospital

Phase 2

1 4

PBR28

NNational Institute of Mental Health (NIMH)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

Phase 2Active, not recruiting

Neuroinflammation

NCT05128903

Clinical

Trials by Indication[1]

Neuroinflammation1 trial

Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05128903·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DPA714. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DPA714 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DPA714. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

DPA714

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2035

Trials by Indication[1]

Neuroinflammation1 trial

References

Drug Info

Quick Facts

Related News